TR199903048T2 - Su i�inde ya�l� a�� compositionalar� - Google Patents

Su i�inde ya�l� a�� compositionalar�

Info

Publication number
TR199903048T2
TR199903048T2 TR1999/03048T TR9903048T TR199903048T2 TR 199903048 T2 TR199903048 T2 TR 199903048T2 TR 1999/03048 T TR1999/03048 T TR 1999/03048T TR 9903048 T TR9903048 T TR 9903048T TR 199903048 T2 TR199903048 T2 TR 199903048T2
Authority
TR
Turkey
Prior art keywords
compositionalar
inde
additives
oil
triglycerides
Prior art date
Application number
TR1999/03048T
Other languages
Turkish (tr)
Inventor
Garcon Nathalie
Marie Christine Aline Fran�Oise Momin Patricia
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR199903048T2 publication Critical patent/TR199903048T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Elimizdeki bulus, yag damla çapi genis çapta 300-600 nm olan, trigliseridlerden olusan gelistirilmis kararli su içindeki yag emülsiyonalari ve bunlarin asi ilaveleri (katkilari) olarak kullanimlari ile ilgilidir.The present invention relates to oil emulsions developed in triglycerides of 300-600 nm with a wide diameter of oil, and their use as additives (additives).

TR1999/03048T 1997-06-11 1998-06-03 Su i�inde ya�l� a�� compositionalar� TR199903048T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Publications (1)

Publication Number Publication Date
TR199903048T2 true TR199903048T2 (en) 2000-08-21

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03048T TR199903048T2 (en) 1997-06-11 1998-06-03 Su i�inde ya�l� a�� compositionalar�

Country Status (17)

Country Link
EP (1) EP0999852A1 (en)
JP (1) JP2002504106A (en)
KR (1) KR20010013644A (en)
CN (1) CN1260723A (en)
AR (1) AR012959A1 (en)
AU (1) AU728759B2 (en)
BR (1) BR9810614A (en)
CA (1) CA2293444A1 (en)
CO (1) CO4940401A1 (en)
GB (1) GB9711990D0 (en)
HU (1) HUP0004001A3 (en)
IL (1) IL133126A0 (en)
NO (1) NO996133L (en)
PL (1) PL337488A1 (en)
TR (1) TR199903048T2 (en)
WO (1) WO1998056414A1 (en)
ZA (1) ZA984969B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1154790B1 (en) * 1999-02-26 2004-10-20 Chiron S.r.l. Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
BRPI0010612B8 (en) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
HUP0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
PT1889630E (en) 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vaccines comprising mage antigen linked to protein d fragment
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
CN1555253A (en) * 2001-09-13 2004-12-15 ������ѧ�����о�Ժ Oily composition of taxol,preparation for chemical therapeutic embolism and their producing method
EP1547607A4 (en) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co Bacterial cell wall skeleton component preparation
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa Methods for vaccinating against malaria
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US20090263470A1 (en) 2004-05-28 2009-10-22 Beth-Ann Coller Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
PE20061428A1 (en) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa VACCINE FORMULATION INCLUDING AN OIL EMULSION ADJUVANT IN WATER AND 3D-MPL
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945252B1 (en) * 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JO2813B1 (en) 2005-12-22 2014-09-15 جلاكسو سميث كلاين بايولوجيكالز اس.ايه Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX337528B (en) 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Immunogenic composition.
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
SG173377A1 (en) 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101192127B1 (en) 2006-11-03 2012-10-17 쉐링-프라우 리미티드 Canine lyme disease vaccine
MX362698B (en) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa NOVEL METHOD and COMPOSITIONS.
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PT2167121E (en) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AP2010005166A0 (en) 2007-08-13 2010-02-28 Glaxosmithkline Biolog Sa Vaccines
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2010148111A1 (en) 2009-06-16 2010-12-23 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and improved methods of making the same
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
JP2014501225A (en) 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
MX354752B (en) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Heterologous prime boost vaccination regimen against malaria.
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP6294076B2 (en) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ Multimeric peptide
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX2014002769A (en) 2011-09-16 2014-06-11 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile.
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US9982034B2 (en) 2012-10-24 2018-05-29 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6306700B2 (en) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ Modified albumin and use thereof
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138B1 (en) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077434A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EA201691348A1 (en) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют ONE-FLAKE VACCINE COMPOSITIONS
CA2935722A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS
AR102547A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
UA125378C2 (en) 2016-03-14 2022-03-02 Універшітетет І Осло Engineered immunoglobulins with altered fcrn binding
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN111315362A (en) 2017-06-15 2020-06-19 传染病研究所 Nanostructured lipid carriers and stable emulsions and uses thereof
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
US11730802B2 (en) 2017-11-03 2023-08-22 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN112638936A (en) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 Adenovirus polynucleotides and polypeptides
CN112601545A (en) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 Process and vaccine
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
MX2021014363A (en) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composition and method for spray drying an adjuvant vaccine emulsion.
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
CA2293444A1 (en) 1998-12-17
AR012959A1 (en) 2000-11-22
CN1260723A (en) 2000-07-19
JP2002504106A (en) 2002-02-05
HUP0004001A3 (en) 2001-07-30
AU728759B2 (en) 2001-01-18
KR20010013644A (en) 2001-02-26
HUP0004001A2 (en) 2001-03-28
GB9711990D0 (en) 1997-08-06
AU8336598A (en) 1998-12-30
CO4940401A1 (en) 2000-07-24
ZA984969B (en) 1999-12-09
PL337488A1 (en) 2000-08-28
IL133126A0 (en) 2001-03-19
WO1998056414A1 (en) 1998-12-17
NO996133L (en) 2000-01-26
BR9810614A (en) 2000-09-12
EP0999852A1 (en) 2000-05-17
NO996133D0 (en) 1999-12-10

Similar Documents

Publication Publication Date Title
TR199903048T2 (en) Su i�inde ya�l� a�� compositionalar�
DE69532917D1 (en) FUEL OIL COMPOSITION WITH POLYOXYALKYLENE
ITME940002A0 (en) HYDROCARBONS, AQUEOUS, FUELS AND ADDITIVES COMPOSITIONS
DE69701575T2 (en) FUEL OIL COMPOSITIONS
CA2226599A1 (en) Environmentally friendly diesel fuel
ATE290057T1 (en) FUEL LUBRICANT ADDITIVE
CA2256301A1 (en) Fuel lubricity from blends of a diethanolamine derivative and biodiesel
FI20011065A (en) Diesel Fuel Composition
DE69520140T2 (en) Aryl-n-alkylacridanthiocarboxylate derivatives that can be used for chemiluminescence detection
PT902824E (en) FUEL ADDITIVES
DE69006029T2 (en) Hydrocarbon fuel compositions and additives therefor.
BR0100233B1 (en) additive to improve the cold flow properties of intermediate distillates, fuel oils and use of such additive.
DE69421784T2 (en) Fuel compositions, and additives therefor
DE69921281D1 (en) Fuels with increased lubrication properties
NO992313L (en) Stabilized water nanocluster fuel emulsions designed by quantum chemistry
NO993791L (en) Alcohols as lubricant additives for distillate fuel
AUPR201500A0 (en) Methods for identifying pre-neoplastic and neoplastic states in mammals
ID20056A (en) LUBRIC OIL, COMPOSITION LUBRIC OIL AND COMPOSITION OF OIL FUEL
BR9612420A (en) Solvent-free coating compositions that can be cured with low emissions
DE69804804D1 (en) IMPROVED FUEL OIL COMPOSITIONS
DE69624690T2 (en) FUEL OIL ADDITIVES AND COMPOSITIONS
TR200001227T2 (en) Fuel composition and mixture.
ID28913A (en) DIESEL FUEL COMPOSITION
BR9900821A (en) Process for improving the appearance of a floor polishing composition, vehicle composition for floor polishing, and use of divalent copper ion.
DE50013786D1 (en) POLYURETHANOUS FIBERS WITH INCREASED STRENGTH